Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 63Specimen Handling 58pembrolizumab 40enzalutamide 38Nivolumab 32Gemcitabine 30Docetaxel 28Biopsy 25Prednisone 23Abiraterone Acetate 21apalutamide 20Androgen Antagonists 19Radiosurgery 18Cisplatin 18darolutamide 16cabozantinib 16abiraterone 16Radiotherapy 16enfortumab vedotin 15Radiation 14Ipilimumab 13belzutifan 12Pluvicto 12Mitomycin 12olaparib 11erdafitinib 11durvalumab 11atezolizumab 11X-Rays 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
pirarubicin × Genitourinary × 30 days × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡